Introduction {#sec1}
============

India has been affected by chikungunya fever (CHIKF) every two to three decades since the 1960s [@bib1]. The latest pandemic that occurred in several parts of the globe in 2005 resulted in huge outbreaks in India, resulting in huge loss of disability-adjusted life-years and a major public health concern in the country [@bib2], [@bib3], [@bib4]. In 2010, Delhi witnessed an outbreak [@bib5], and since then, CHIKF has been in a decline; only sporadic cases been reported. However, in August 2016, another massive outbreak broke in New Delhi and the National Capital Region, resulting in thousands of households being bedridden (<http://nvbdcp.gov.in/chik-cd.html>). The present report describes the status of the CHIKF outbreak in New Delhi during 2016, with an emphasis on the status of coinfections and comorbid conditions of recruited patients.

Methods {#sec2}
=======

Between August and December 2016, a total of 5180 patients sought care at the Department of Microbiology and the outpatient wards of Safdarjung Hospital for suspected CHIKF. Of these, 600 patients were enrolled onto this study, which was part of an ongoing project that was cleared by the institutional ethical board (IEC/VMMC/SJH/Project/February-2016/575, ICGEB/IEC/2016/01 and Version-3). Blood samples were collected, and clinical information such as age, gender, symptoms, joint movement and onset of fever were documented. Sera were separated and stored at −80°C until further use. Admission criteria also included patients with complications and associated comorbid conditions. Cerebrospinal fluid was collected from two such patients and stored at −80°C. All sera samples were subjected to IgM serology for the presence of dengue virus (DENV) and chikungunya virus (CHIKV) using government-recommended kits from National Institute of Virology, Pune, NS1. Antigen for DENV was detected using Qualpro diagnostics. Quantitative real-time PCR (qPCR) for the presence of CHIKV RNA was performed using previously published primers [@bib6], and Zika virus RNA was tested using qPCR kits from Altona Diagnostics. Cerebrospinal fluid was tested directly and was also inoculated in C6/36 cells to evaluate the presence of CHIKV through qPCR. qPCR-positive bands were eluted from gel, sequenced and phylogenetic analysis performed for the sequences.

Results and discussion {#sec3}
======================

A total of 2982 patients tested positive for CHIKF out of the total 5180, resulting in an incidence rate of 58% during the collection period. Of these, demographic and laboratory data were collected for a total of 600 patients enrolled onto the study ([Table 1](#tbl1){ref-type="table"}). The median age of patients was 35 years (range, 11--68 years). Male-to-female ratio was 1.1:1.0. At the time of patient recruitment, onset of fever ranged from 1 to 30 days (median, 4 days).Table 1Demographic and laboratory dataTable 1CharacteristicValue**Demographic (*n* = 600)**Age (years) Mean35 Range11--68Sex, M:F1.1:1Onset of fever (days) Median4 Range1--30**Clinical (*n* = 150)**Patients with: Fever with chills9 (6%) Itching35 (23.3%), severe 2 (1.3%) Nausea12 (8%) Rashes46 (30.6%), severe 11 (7.3%), moderate 21 (14.0%) Diarrhoea2 (1.3%) Vomiting5 (3.3%) Ulcers2 (1.3%) Headache7 (5%)Musculoskeletal Swelling59 (39%), severe 2 (1.3%) Restricted movement of the joints146 (97%), extreme 41 (27%) Backache3 (2%) Morning stiffness32 (21.3) Body ache3 (2%) Pedal oedema22 (14.6%) Partial paraparesis4 (2.6%)**Comorbid Conditions (*n* = 12)**Hypotension with additional complications3 (2%)Hypertonia2 (1.3%)Decreased sensation of pain, touch and temperature2 (1.3%)Lipoma in head2 (1.3%)Chest pain2 (1.3%)Encephalopathy and encephalitis2 (1.3%)Dermatomyositis1 (0.5%)Respiratory presentation1 (0.5%)Severe thrombocytopenia1 (0.5%)Demyelinating disorder presenting as traverse myelitis1 (0.5%)Intrauterine death1 (0.5%)Mortality rate2 (1.3%)**Diagnostics (*n* = 600)**CHIKV IgM positive420 (70%)CHIKV qPCR positive145 (24.17%)CHIKV IgM and qPCR positive40 (6.67%)Only CHIKV IgM positive (CHIKV qPCR negative)244 (40.67%)Only CHIKV qPCR positive (CHIKV IgM negative)103 (17.17%)DENV IgM positive168 (28%)DENV NS1 positive3 (0.5%)ZIKV qPCR0**Coinfection Status (*n* = 600)**CHIKV/DENV CHIKV qPCR/DENV IgM40 (6.67%) CHIKV qPCR/DENV NS10 (0%) CHIKV IgM/DENV IgM112 (18.67%) CHIKV IgM/DENV NS11 (0.5%) Overall coinfection (CHIKV IgM/qPCR/DENV IgM/NS1152 (25.33%)[^1]

Serologic investigations of the samples revealed that 420 samples (70%) were positive for CHIKV IgM, 145 samples (24.17%) were positive by qPCR and 40 samples (6.67%) were positive by both methods. With respective to dengue, DENV IgM tested positive in 168 samples (28%), and only three samples tested positive for the NS1 antigen. On the basis of these investigations, it was observed that 152 samples (25.33%) tested positive for both CHIKV and DENV, as measured by qPCR, IgM or both. None of the samples tested positive for Zika virus RNA by quantitative qPCR.

Analysis of the clinical features in 150 patients revealed that 97% (*n* = 146) of patients had restricted movements of the joints, with 41 patients displaying extreme restriction and requiring help in even lifting their limbs ([Table 1](#tbl1){ref-type="table"}). Swelling in joints was observed in 39% of the patients, with severe swelling seen in two patients. Itching and rashes occurred in 23.3% (*n* = 35) and 30.6% (*n* = 46) of patients respectively, with variable levels of severity ([Table 1](#tbl1){ref-type="table"}). Details of clinical features, musculoskeletal involvement and comorbid conditions are documented in [Table 1](#tbl1){ref-type="table"}.

Complications in CHIKF during this outbreak were seen in 12 patients during the time of sample collection ([Table 1](#tbl1){ref-type="table"}). Of these, hypotension was seen in three patients, with additional complication such as abdominal tenderness, coinfection with dengue and hematemesis. Encephalopathy/encephalitis was seen in two patients. Other comorbid conditions are listed in [Table 1](#tbl1){ref-type="table"}. Cerebrospinal fluid that was collected from two patients with comorbid conditions was cultured and revealed positivity for CHIKV through qPCR.

PCR products corresponding to complete gene of the structural envelope protein E1, from 21 samples including the cerebrospinal fluid samples, were purified and sequenced. Sequence analysis revealed that all samples belonged to Asian and East-Central South African (ECSA) genotype at the CHIKV E1 region ([Fig. 1](#fig1){ref-type="fig"}). Nucleotide sequence analysis performed on the whole *E1* gene revealed variations at 40 nucleotide positions when compared to the 1953 Tanzanian strain (accession no. 045811.1). Of these, 29 variations resulted in synonymous and 11 variations in nonsynonymous mutations. At the amino acid level, 11 amino acid substitutions---namely, R123K, T145S, V179M, K211E, P232Q, I261D, M269V, D284E, I317V/M, V322A and N389K---were observed. Of these mutations, K211E, M269V and D284E have been reported previously in Delhi samples [@bib5]. With respect to K211E, the mutation has been seen in all CHIKV samples after 2010 episode since its initial report in 2006 in a single sample in South India [@bib7]. This mutation has been observed until 2014 in all reported samples [@bib8]. However, for the first time, in the present study, two samples from the 2016 outbreak revealed reversion of wild-type lysine from the mutant glutamic acid. Considering that this amino acid site showed positive selection for the mutation in our previous study [@bib5], in-depth analyses are warranted to understand the implication of this reversion in evolution of CHIKV and its impact in disease prevalence.Fig. 1Genome sequence analysis of chikungunya virus (CHIKV) E1 region of all samples confirms that all samples belonged to Asian and East-Central South African (ECSA) genotype.Fig. 1

Conclusions {#sec4}
===========

Since 2010, CHIKF had been declining in the country [@bib9] until the current outbreak in 2016. However, chikungunya has been reported as a coinfection in almost 10% of DENV cases in recent studies [@bib10]. The present outbreak reveals that the percentage is much higher, with 25% of CHIKF cases to be positive for DENV RNA antibodies, thereby making it imperative to check all suspected DENV cases for possible chikungunya infection as well. The current outbreak reports neurologic complications in CHIKF patients, as evidenced in a recent study on samples collected during the same outbreak in another hospital [@bib11].

The chikungunya outbreak in 2016 has left long-lasting effects on the affected population. Post--acute phase complications are still being reported in the hospitals, and detailed analyses of the aftermath of the outbreak will be important to understand the actual impact of the current outbreak.
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